Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Advertisement
Christopher Wallis, MD, PhD, FRCSCSUO 2023 | December 1, 2023
Drs. Faltas and Wallis delve into the genomics of UTUC, including the evolution of disease and FGFR inhibition potential.
View More
Christopher Wallis, MD, PhD, FRCSCSUO 2023 | December 1, 2023
Drs. Murray and Wallis discuss optimal patient selection, size criteria, and surgical ablation and chemoablation together.
Emily MenendezUpper Tract Urothelial Carcinoma | November 21, 2023
The nomogram outperformed 2 conventional models in predictive accuracy and showed higher benefit in decision curve analysis.
Roger Li, MDUpper Tract Urothelial Carcinoma | November 15, 2023
Dr. Li details what his study results suggested about ctDNA’s prognostic implications for survival in patients with UTUC.
Katy MarshallUpper Tract Urothelial Carcinoma | November 14, 2023
The study compared ureteroscopic surgery with radical nephroureterectomy.
Katy MarshallUpper Tract Urothelial Carcinoma | November 10, 2023
Researchers used whole-genome sequencing and a 152-gene panel to study the DNA of patients with high-risk UTUC.
Katy MarshallUpper Tract Urothelial Carcinoma | October 26, 2023
Investigators performed IHC of 4 DNA mismatch repair gene-related proteins (MMRPs) on all UTUC specimens.
Emily MenendezUpper Tract Urothelial Carcinoma | October 13, 2023
In URS and RIRS, pulse shapes were significantly different, with Ho:YAG being used in long-pulse and TFL in short-pulse mode.
Emily MenendezUpper Tract Urothelial Carcinoma | September 22, 2023
The novel nomogram demonstrated perfect performance in discrimination ability and clinical net benefit.
Emily MenendezUpper Tract Urothelial Carcinoma | September 8, 2023
Older patients over 70 years of age need improved care and management of UTUC to improve their outcomes.
Emily MenendezUpper Tract Urothelial Carcinoma | August 18, 2023
Patients who had initiated AC 90 days after RNU were examined to determine a relation between treatment efficacy and timing.
David Ambinder, MDUpper Tract Urothelial Carcinoma | July 31, 2023
Dr. Surena F. Matin shared valuable insights on lymph node dissection and kidney-sparing management for UTUC.
David Ambinder, MDUpper Tract Urothelial Carcinoma | July 31, 2023
Dr. Katie S. Murray provided insight into identifying candidates for kidney-sparing management of upper tract disease.
Emily MenendezUpper Tract Urothelial Carcinoma | July 13, 2023
The implications of VH have been thoroughly studied in bladder cancer, but further investigation is needed in UTUC.
Surena F. Matin, MDUpper Tract Urothelial Carcinoma | August 15, 2023
Does the OLYMPUS trial have practice-changing potential for patients with low-grade, low-volume UTUC?
Surena F. Matin, MDUpper Tract Urothelial Carcinoma | July 28, 2023
Breaking down kidney-sparing management for UTUC, ideal patients, and SOC for endoscopic resection or ureter resection.
Surena F. Matin, MDUpper Tract Urothelial Carcinoma | July 24, 2023
Data supporting lymph node dissection at time of surgery for UTUC, as well as the risk factors for individual patients.
Katie S. Murray, DOUpper Tract Urothelial Carcinoma | July 24, 2023
Detailing the mitomycin gel adverse events, as well as advice for private practice urologists when offering mitomycin gel.
Katie S. Murray, DOUpper Tract Urothelial Carcinoma | July 24, 2023
Ideal candidates for nephron sparing management for upper tract disease, as well as candidates for mitomycin gel.
Petros Grivas, MD, PhDUpper Tract Urothelial Carcinoma | July 24, 2023
ICIs for upper tract disease after upfront chemotherapy, along with the emerging role of targeted therapies.
Advertisement
Advertisement
Advertisement